BioSpace News Archive

Drug Development

NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanophysics-based approaches to expand treatment possibilities for patients with cancer, today announced the publication of preclinical findings with the University of Texas MD Anderson Cancer Center (MD Anderson) in the International Journal of Radiation Oncology, Biology, Physics (Red Journal).

September 28, 2021
·
8 min read
Genetown

Genocea to Present at Upcoming Conferences

Genocea Biosciences, Inc. announced that senior leadership plans to present at the following conferences in October. Scientific conferences: Event: AACR: Tumor Immunology and Immunotherapy

September 28, 2021
·
3 min read